With the 2020 approval of Nivolumab and Ipilimumab for metastatic NSCLC with PDL1 >1%, what is your preferred first line treatment option for a fit patient who is PDL1 positive (1-49%) with no driver mutations?  

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Yuma Regional Medical Center Cancer Center
I would add that patients who recurred after durva...
Medical Oncologist at University of Michigan Medical School
Agree with @Shadia I. Jalal. I would use chemo-imm...
Sign in or Register to read more